Stem cell transplantation in adults with acute myelogenous leukemia, normal cytogenetics, and the FLT3-ITD mutation

被引：3

作者：

Berman, Ellin ^{[1
,2
]}

Maloy, Molly ^{[2
,3
]}

Devlin, Sean ^{[2
,4
]}

Jhanwar, Suresh ^{[2
,5
]}

Papadopoulos, Esperanza ^{[2
,3
]}

Jakubowski, Ann ^{[2
,3
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY 10065 USA

[2] Weill Cornell Med Coll, New York, NY 10065 USA

[3] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Manow Transplant Serv, New York, NY 10065 USA

[4] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA

[5] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA

来源：

LEUKEMIA RESEARCH | 2016年 / 40卷

关键词：

AML; FLT3-ITD; Stem cell transplant; ACUTE MYELOID-LEUKEMIA; ALLOGENEIC TRANSPLANTATION; 1ST REMISSION; AML; BLOOD; ENGRAFTMENT; FLT3/ITD; RELAPSE; IMPACT;

D O I：

10.1016/j.leukres.2015.11.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Following chemotherapy, patients with acute myelogenous leukemia (AML), normal cytogenetics, and the FLT3-ITD mutation have shorter survival compared to wild type (WT) patients. To determine the role of stem cell transplantation (SCT), we performed a retrospective review of adult patients with AML who underwent SET at our center between January 1, 2007 and December 31, 2011. Of the 200 patients transplanted, 79 patients (40%) had normal cytogenetics; of these, 17(22%) had the FLT3-ITD mutation, 35 were WT (44%), and 27 (34%) did not have FLT3 testing performed. Clinical characteristics were similar in each group. At four years, overall survival (OS) between FLT3 positive and WT groups was similar: 0.54 (95% CI 0.29-0.75) versus 0.73 (95% CI 0.53-0.99), p = 0.18. Relapse rates were also similar, 0.09 (95% CI 0.02-0.21) versus 0.12 (95% CI: 0.02-0.32); p = 0.67. We conclude that SCT can abrogate the poor prognosis in FLT3-ITD positive patients. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：33 / 37

页数：5

共 28 条

[1]

Boulad F., 2012, BLOOD, V120, P3144

[2] Phase II trial of a chemotherapy-only regimen of busulfan, melphalan, fludarabine and R-ATG followed by allogeneic T-cell depleted (TCD) hematopoietic stem cell transplants (HSCT) for the treatment of myeloid malignancies [J].

Boulad, Farid ;

Jakubowski, Ann ;

Papadopoulos, Esperanza ;

Hsu, Katharine C. ;

Perales, Miguel Angel ;

van den Brink, Marcel ;

Young, James W. ;

Chiu, Michelle ;

Keman, Nancy A. ;

Prockop, Susan E. ;

Scaradavou, Andromachi ;

Small, Trudy N. ;

Castro-Malaspina, Hugo ;

O'Reilly, Richard J. .

BLOOD, 2007, 110 (11) :878A-878A

[3] Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis [J].

Brunet, Salut ;

Labopin, Myriam ;

Esteve, Jordi ;

Cornelissen, Jan ;

Socie, Gerard ;

Iori, Anna P. ;

Verdonck, Leo F. ;

Volin, Liisa ;

Gratwohl, Alois ;

Sierra, Jorge ;

Mohty, Mohamad ;

Rocha, Vanderson .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (07) :735-741

[4] Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Arm-Combined Prospective Analysis by the German AML Intergroup [J].

Buechner, Thomas ;

Schlenk, Richard F. ;

Schaich, Markus ;

Doehner, Konstanze ;

Krahl, Rainer ;

Krauter, Juergen ;

Heil, Gerhard ;

Krug, Utz ;

Sauerland, Maria Cristina ;

Heinecke, Achim ;

Spaeth, Daniela ;

Kramer, Michael ;

Scholl, Sebastian ;

Berdel, Wolfgang E. ;

Hiddemann, Wolfgang ;

Hoelzer, Dieter ;

Hehlmann, Ruediger ;

Hasford, Joerg ;

Hoffmann, Verena S. ;

Doehner, Hartmut ;

Ehninger, Gerhard ;

Ganser, Arnold ;

Niederwieser, Dietger W. ;

Pfirrmann, Markus .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) :3604-3610

[5] Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:: results from Cancer and Leukemia Group B (CALGB 8461) [J].

Byrd, JC ;

Mrózek, K ;

Dodge, RK ;

Carroll, AJ ;

Edwards, CG ;

Arthur, DC ;

Pettenati, MJ ;

Patil, SR ;

Rao, KW ;

Watson, MS ;

Koduru, PRK ;

Moore, JO ;

Stone, RM ;

Mayer, RJ ;

Feldman, EJ ;

Davey, FR ;

Schiffer, CA ;

Larson, RA ;

Bloomfield, CD .

BLOOD, 2002, 100 (13) :4325-4336

[6]

Collins NH, 1991, BONE MARROW STEM CEL, P171

[7] Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell-Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous Leukemia in First Remission: Results of the Blood and Marrow Transplant Clinical Trials Network Protocol 0303 [J].

Devine, Steven M. ;

Carter, Shelly ;

Soiffer, Robert J. ;

Pasquini, Marcelo C. ;

Hari, Parameswaran N. ;

Stein, Anthony ;

Lazarus, Hillard M. ;

Linker, Charles ;

Stadtmauer, Edward A. ;

Alyea, Edwin P., III ;

Keever-Taylor, Carolyn A. ;

O'Reilly, Richard J. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (09) :1343-1351

[8] Role of Allogeneic Transplantation for FLT3/ITD Acute Myeloid Leukemia: Outcomes from 133 Consecutive Newly Diagnosed Patients from a Single Institution [J].

DeZern, Amy E. ;

Sung, Anthony ;

Kim, Sharon ;

Smith, B. Douglas ;

Karp, Judith E. ;

Gore, Steven D. ;

Jones, Richard J. ;

Fuchs, Ephraim ;

Luznik, Leo ;

McDevitt, Michael ;

Levis, Mark .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (09) :1404-1409

[9] Selection of CD34-positive blood cells for allogeneic transplantation:: Approaches to optimize CD34-cell recovery, purity, viability, and T-cell depletion [J].

Fritsch, G ;

Scharner, D ;

Fröschl, G ;

Buchinger, P ;

Peters, C ;

Matthes, S ;

Witt, V ;

Gadner, H .

ONKOLOGIE, 2000, 23 (05) :449-456

[10] Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics:: a study of the AML Study Group Ulm [J].

Fröhling, S ;

Schlenk, RF ;

Breitruck, J ;

Benner, A ;

Kreitmeier, S ;

Tobis, K ;

Döhner, H ;

Döhner, K .

BLOOD, 2002, 100 (13) :4372-4380

← 1 2 3 →